MX2023001469A - Formas cristalinas de un inhibidor de la o-glucoproteina-2-acetami do-2-desoxi-3-d-glucopiranosidasa. - Google Patents
Formas cristalinas de un inhibidor de la o-glucoproteina-2-acetami do-2-desoxi-3-d-glucopiranosidasa.Info
- Publication number
- MX2023001469A MX2023001469A MX2023001469A MX2023001469A MX2023001469A MX 2023001469 A MX2023001469 A MX 2023001469A MX 2023001469 A MX2023001469 A MX 2023001469A MX 2023001469 A MX2023001469 A MX 2023001469A MX 2023001469 A MX2023001469 A MX 2023001469A
- Authority
- MX
- Mexico
- Prior art keywords
- copyranosidase
- acetamido
- deoxy
- glycoprotein
- glu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063060281P | 2020-08-03 | 2020-08-03 | |
| PCT/US2021/044341 WO2022031701A1 (en) | 2020-08-03 | 2021-08-03 | Crystaline forms of an o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001469A true MX2023001469A (es) | 2023-06-16 |
Family
ID=77640732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001469A MX2023001469A (es) | 2020-08-03 | 2021-08-03 | Formas cristalinas de un inhibidor de la o-glucoproteina-2-acetami do-2-desoxi-3-d-glucopiranosidasa. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230286972A1 (https=) |
| EP (1) | EP4188925A1 (https=) |
| JP (1) | JP7789056B2 (https=) |
| KR (1) | KR20230061395A (https=) |
| CN (1) | CN116917284A (https=) |
| AR (1) | AR123132A1 (https=) |
| AU (1) | AU2021322186A1 (https=) |
| BR (1) | BR112023002013A2 (https=) |
| CA (1) | CA3188250A1 (https=) |
| CL (1) | CL2023000327A1 (https=) |
| CO (1) | CO2023002543A2 (https=) |
| CR (1) | CR20230118A (https=) |
| IL (1) | IL300365A (https=) |
| MX (1) | MX2023001469A (https=) |
| PE (1) | PE20231168A1 (https=) |
| TW (1) | TW202220984A (https=) |
| UY (1) | UY39366A (https=) |
| WO (1) | WO2022031701A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2602139B (en) * | 2020-12-18 | 2024-07-24 | Nexeon Ltd | Electroactive materials for metal-ion batteries |
| WO2025184490A1 (en) | 2024-03-01 | 2025-09-04 | Biogen Ma Inc. | N-[4-fluor-5-[[(2s, 4 r)-4-[(6-methoxy-4-pyrimidinyl)oxy]- 2-methyl-1-pyrrolidinyl] methyl ]-2-thiazolyl]acetamid for use in the treatment of alzheimer disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2780014A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| US9051269B2 (en) | 2011-11-18 | 2015-06-09 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013078320A1 (en) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP5989805B2 (ja) | 2012-02-10 | 2016-09-07 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | メチル基変更酵素の調節物質、組成物及びその使用 |
| MA38341B1 (fr) | 2013-02-11 | 2018-11-30 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| EP3555087A1 (en) | 2016-12-16 | 2019-10-23 | Janssen Pharmaceutica NV | Monocyclic oga inhibitor compounds |
| TWI654978B (zh) | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5－甲基－1,2,4－二唑－3－基化合物 |
| WO2018154133A1 (en) | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
| US12180205B2 (en) * | 2018-09-19 | 2024-12-31 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
-
2021
- 2021-08-03 WO PCT/US2021/044341 patent/WO2022031701A1/en not_active Ceased
- 2021-08-03 PE PE2023000189A patent/PE20231168A1/es unknown
- 2021-08-03 TW TW110128540A patent/TW202220984A/zh unknown
- 2021-08-03 KR KR1020237007569A patent/KR20230061395A/ko active Pending
- 2021-08-03 CN CN202180066901.9A patent/CN116917284A/zh active Pending
- 2021-08-03 IL IL300365A patent/IL300365A/en unknown
- 2021-08-03 JP JP2023507579A patent/JP7789056B2/ja active Active
- 2021-08-03 BR BR112023002013A patent/BR112023002013A2/pt not_active Application Discontinuation
- 2021-08-03 AU AU2021322186A patent/AU2021322186A1/en active Pending
- 2021-08-03 EP EP21766024.0A patent/EP4188925A1/en active Pending
- 2021-08-03 AR ARP210102157A patent/AR123132A1/es unknown
- 2021-08-03 UY UY0001039366A patent/UY39366A/es unknown
- 2021-08-03 MX MX2023001469A patent/MX2023001469A/es unknown
- 2021-08-03 US US18/019,270 patent/US20230286972A1/en active Pending
- 2021-08-03 CA CA3188250A patent/CA3188250A1/en active Pending
- 2021-08-03 CR CR20230118A patent/CR20230118A/es unknown
-
2023
- 2023-02-01 CL CL2023000327A patent/CL2023000327A1/es unknown
- 2023-03-01 CO CONC2023/0002543A patent/CO2023002543A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202220984A (zh) | 2022-06-01 |
| CN116917284A (zh) | 2023-10-20 |
| PE20231168A1 (es) | 2023-07-26 |
| US20230286972A1 (en) | 2023-09-14 |
| AU2021322186A1 (en) | 2023-04-06 |
| BR112023002013A2 (pt) | 2023-05-02 |
| EP4188925A1 (en) | 2023-06-07 |
| CR20230118A (es) | 2023-06-02 |
| CA3188250A1 (en) | 2022-02-10 |
| CO2023002543A2 (es) | 2023-06-09 |
| JP7789056B2 (ja) | 2025-12-19 |
| UY39366A (es) | 2022-02-25 |
| CL2023000327A1 (es) | 2023-10-06 |
| JP2023536911A (ja) | 2023-08-30 |
| IL300365A (en) | 2023-04-01 |
| WO2022031701A1 (en) | 2022-02-10 |
| AR123132A1 (es) | 2022-11-02 |
| KR20230061395A (ko) | 2023-05-08 |
| WO2022031701A9 (en) | 2022-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE361288T1 (de) | N-(3,-dimethylindolin-6-yl)ä2-ä(4- | |
| WO2004007481A3 (en) | Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders | |
| TW200512195A (en) | Benzamide 2-hydroxy-3-diaminoalkanes | |
| MXPA04002785A (es) | Aminas sustituidas para tratamiento de enfermedad de alzheimer. | |
| AP2001002358A0 (en) | Salt forms of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4- pyrrolidin-1-yl-butyl)ureido]-isothiazole-4-carboxilic acid amide and method of production. | |
| WO2002068406A3 (en) | Substituted amine derivatives and their use for the treatment of angiogenesis | |
| MX2023001469A (es) | Formas cristalinas de un inhibidor de la o-glucoproteina-2-acetami do-2-desoxi-3-d-glucopiranosidasa. | |
| BR0314631A (pt) | Derivados de pirrolidona como inibidores de maob | |
| DE60229530D1 (de) | Substituierte piperazine als modulatoren des melanocortinrezeptors | |
| BRPI0411673A (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto | |
| MXPA05012196A (es) | Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos. | |
| MX2023012521A (es) | Formas en estado solido de (s)-n-(3-(2-((r)-1-hidroxipropano-2-il) amino)-6-morfolinopiridin-4-il)-4-metilfenil)-3-(2,2,2-trifluoroe til)pirrolidin-1-carboxamida y sales de las mismas. | |
| EA200800783A1 (ru) | Композиция тразодона для введения один раз в день | |
| WO2003070728A3 (en) | Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders | |
| BRPI0409151A (pt) | uso de derivados de 10-hidróxi-10,11-diidrocarbamazepina para o tratamento de transtornos afetivos | |
| BRPI0509515A (pt) | composto, formulação farmacêutica, uso de um composto método para tratamento de doenças, e, processo para a preparação de um composto | |
| WO2023183428A8 (en) | Mglur5 modulating compounds, compositions, and methods of use | |
| WO2002036118A3 (en) | Heterocyclic derivatives useful as pharmaceutical agents | |
| TW200510351A (en) | Oxazole compounds for the treatment of neurodegenerative disorders | |
| BR0317714A (pt) | Oxazóis como realçadores de mglur1 | |
| AU2002362008A1 (en) | Amine 1,2- and 1,3-diol compounds and their use for treatment of alzheimer's disease | |
| MX2024000903A (es) | Formas cristalinas. | |
| IL163374A (en) | Urea derivatives for treatment or prevention of disorders of the eye | |
| BRPI0512404A (pt) | inibidores de mao-b | |
| HK20095319A1 (en) | Btk inhibitors |